Relmacabtagene autoleucel
瑞基奥仑赛CD19-directed CAR-T therapy transitioning from the 2025 Commercial List (#12) into the 2026 NRDL Negotiated List (#297) across three B-cell lymphoma indications.
China Approval (NMPA)
Approved- Approval Number(s)
- 国药准字S20210035
- Initial Approval Date
- Sep 1, 2021
- Notice Published
- Sep 3, 2021
- MAH
- JW Therapeutics (Shanghai) Co., Ltd. (上海药明巨诺生物科技有限公司)
- Approved Scope
- Adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy; subsequently expanded to r/r FL and r/r MCL.
National Reimbursement
Announced · Effective Jan 1, 2027- 2026 Edition Entry
- Negotiated #297 · Class B
- Agreement Period
- 2027-01-01 to 2028-12-31
- Payment Standard
- * Confidential (marked with asterisk in NHSA PDF)
- 2026 Payment Scope
- Restricted to: (1) Adult r/r LBCL (DLBCL NOS, PMBCL, HGBL double/triple-hit) after ≥2 prior systemic therapies; (2) Adult refractory or ≤24-month relapsed grade 1–3a follicular lymphoma after ≥2 prior lines; (3) Adult r/r mantle cell lymphoma after ≥2 prior lines including a BTK inhibitor.
- 限:1.经过二线或以上系统性治疗后成人患者的复发或难治性大B细胞淋巴瘤,包括弥漫性大B细胞淋巴瘤非特指型、原发纵隔大B细胞淋巴瘤、高级别B细胞淋巴瘤伴MYC和BCL-2和/或BCL-6重排(双打击/三打击淋巴瘤);2.经过二线或以上系统性治疗的成人难治性或24个月内复发的滤泡性淋巴瘤,包括组织学分级为1、2、3a级的滤泡性淋巴瘤;3.经过包括布鲁顿酪氨酸激酶抑制剂(BTKi)治疗在内的二线及以上系统性治疗的成人复发或难治性套细胞淋巴瘤。
Commercial Insurance List
2025 Only (Not in 2026)Previously listed in the 2025 Commercial Insurance Innovative Drug List (#12). Graduated into the 2026 Basic NRDL (#297).
Approved Products, Dosage Forms & Approval Numbers
1 verified NMPA record| Approval No. | Dosage Form & Strength | Event & Scope | Approval / Notice Date | MAH & Source |
|---|---|---|---|---|
| 国药准字S20210035 | Injection (CAR-T) (注射液) | Initial Approval Adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy; subsequently expanded to r/r FL and r/r MCL. 经过二线或以上系统性治疗后成人患者的复发或难治性大B细胞淋巴瘤(r/r LBCL);后续获批滤泡性淋巴瘤(FL)及套细胞淋巴瘤(MCL)适应症。 | Approved: 2021-09-01 Published: 2021-09-03 | JW Therapeutics (Shanghai) Co., Ltd. |
Change Timeline
- (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026
2026 NRDL · Added to Negotiated List
Newly added to 2026 NRDL Negotiated List (#297, Class B, *) across 3 lymphoma indications (r/r LBCL, r/r FL, r/r MCL); transitioned out of the 2025 Commercial List (#12).
Chinese original: 由2025版商保创新药目录(第12项)转入2026版基本医保谈判药品第297项(乙类,支付标准*),覆盖LBCL、FL及MCL三项适应症。
NHSA · PDF p.149Verified 2026-11-20 - (2026-01-01)Commercial List· Catalog published: Dec 7, 2025
2025 Commercial List · Removed in 2026 Edition (#12)
Listed in 2025 Commercial List (#12) for r/r LBCL, FL, and MCL; graduated into the 2026 basic NRDL Negotiated List (#297).
Chinese original: 1.二线及以上成人r/r LBCL;2.二线及以上成人难治性或24个月内复发FL(1-3a级);3.含BTKi在内的二线及以上成人r/r MCL。
NHSA · PDF p.4Verified 2026-11-20 - (2021-09-01)NMPA Approval· Notice published: Sep 3, 2021
NMPA Initial Marketing Approval (国药准字S20210035)
Adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy; subsequently expanded to r/r FL and r/r MCL.
Chinese original: 经过二线或以上系统性治疗后成人患者的复发或难治性大B细胞淋巴瘤(r/r LBCL);后续获批滤泡性淋巴瘤(FL)及套细胞淋巴瘤(MCL)适应症。
NMPA · NMPA Registration S20210035Verified 2026-11-20
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14国家基本医疗保险、生育保险和工伤保险药品目录(2026年)Retrieved 2026-11-20
- NHSAPublished 2025-12-07商业健康保险创新药品目录(2025年)Retrieved 2026-11-20 · 医保发〔2025〕33号附件
- NMPA国家药品监督管理局政务服务门户与药品查询Retrieved 2026-11-20
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20